HOME >> MEDICINE >> NEWS
Structure of key cancer drug target identified

Researchers from Monash's Department of Biochemistry and Molecular Biology have determined the structure of the protein JAK2 kinase, a discovery with huge implications for the design and development of new cancer drugs.

NHMRC Industry Research Fellow Dr Isabelle Lucet, from Monash's Protein Crystallography Unit headed by Dr Jamie Rossjohn, was part of the team that determined the structure. JAK2 kinase was the driving force for many cancers and cardiovascular disorders, she said.

The research, partly funded by a $1.2 million Australian Research Council Linkage Grant, was a joint project between drug development company Cytopia Limited and the Protein Crystallography Unit.

The JAK kinases, which were first discovered by Cytopia's chief scientific officer Dr Andrew Wilks, are a well-validated drug target.

Dr Lucet said the discovery of JAK2 kinase's structure had allowed an internationally competitive structure-based drug design on JAK kinase inhibitors to begin.

"This will help the development of drugs for cancer and other disorders by assisting with the design of specific molecules."

She said the high expertise of the Monash research team, combined with the drug discovery capability of Cytopia, would undoubtedly enable more selective drug targets to be developed against diseases where the JAK kinases play a pivotal role.

Dr Lucet said the new discovery would allow the rapid growth of a portfolio of phase I therapeutics.


'"/>

Contact: Penny Fannin
61-3-9905-5828
Research Australia
25-Oct-2005


Page: 1

Related medicine news :

1. Structure essential for brain remodeling identified
2. Structure of viral harpoon protein reveals how viruses enter cells
3. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
4. Survival differences by race most apparent in advanced stages of breast cancer
5. Stomach cancer rate set to fall further 25 percent over next decade
6. MRI finds breast cancer before it becomes dangerous
7. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
8. New cause of tamoxifen resistance in breast cancer cells discovered at Lombardi
9. Pathway links inflammation, angiogenesis and breast cancer
10. Using MRI for diagnosis could help prevent breast cancer progression
11. Electric fields have potential as a cancer treatment

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:7/27/2017)... ... ... Team Novo Nordisk, the world’s first all-diabetes professional cycling team, is bringing Isle ... the remainder of the 2017 season. One of our best development riders, Brand is ... , “Every season we are excited to move an athlete from our pipeline up ...
(Date:7/26/2017)... (PRWEB) , ... July 26, 2017 , ... Capillus, LLC ... treat hereditary hair loss. The new Flexible Fitting Design offers a more comfortable, adaptable ... LLC is delighted with the improvements to the home-use laser therapy caps intended to ...
(Date:7/26/2017)... ... July 26, 2017 , ... A major challenge many labs face is ... samples and a lengthy freeze dry cycle are a few common challenges that can ... as well as new accessories and advancements in laboratory freeze dryers that will improve ...
(Date:7/26/2017)... ... 2017 , ... It's time to sign up for the new One-A-Month Essential Oil ... Heshelow, founder of Sublime Naturals and author of numerous books on essential oils. , ... by the 5th. , Two items are included in the December mailing. ...
(Date:7/26/2017)... Jupiter, Florida (PRWEB) , ... July 26, 2017 ... ... care for dogs and cats has opened in Jupiter. The state of ... patients (cardiology) and class leading treatments with a goal of providing heart patients ...
Breaking Medicine News(10 mins):
(Date:7/26/2017)... 2017 Sancilio Pharmaceuticals Company, Inc. (SPCI) today ... evaluating Altemia TM , an oral therapy for pediatric ... Disease (SCD). The SCOT Trial, is a double-blind, placebo-controlled, ... of Altemia TM in pediatric patients aged 5-17 ... 125274. "The completion ...
(Date:7/24/2017)... Mich. , July 24, 2017  Diplomat Pharmacy, ... it will release its second quarter 2017 operating results ... a conference call to follow at 5:00 p.m. ET. ... participants may listen to a live broadcast of the ... callers, and referencing participant code 51641230 approximately 15 minutes ...
(Date:7/20/2017)... , July 20, 2017  Prime Therapeutics LLC (Prime) released ... , M.D., following today,s Institute for Clinical and Economic Review,s ... on the effectiveness and value of abuse-deterrent formulations (ADF) of ... policy roundtable at the meeting. ... material cost benefit to the use of abuse-deterrent formulations (ADF) ...
Breaking Medicine Technology:
Cached News: